Abstract

Disclosed are methods for treating various cancers. Methods encompass the administration of a first drug such as AP23573, temsirolimus or everolimus in combination with a second drug selected from Remicade, Humira, Enbrel, Raptiva, Abatacept, Actermra, Cimzia or anakinra. The methods are aimed at providing a desirable therapeutic window while maintaining prior, if not higher, dose levels of the first drug.

IPC Classes  ?

• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof

Abstract

The invention provides the use of a combination of an mTOR inhibitor and capecitabine in the treatment of cancer.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The invention features methods for treatment of a patient in need thereof with the administration of mammalian target of rapamycin (mTOR) inhibitors such as sirolimus, temsirolimus, everolimus or rapamycin analogs including AP23573, especially to a cancer patient for 4 or 5 consecutive days per week. The mTOR inhibitor therapy can be used for a wide range of cancers including prostrate, pancreas, ovary, lung, breast, bladder, colon, brain, head and neck, endometrium, leukemia, lymphoma and sarcoma.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61P 35/00 - Antineoplastic agents

Abstract

This invention concerns a new family of phosphorus-containing macrocycles containing various phosphonate- and phosphonate-containing moieties.

IPC Classes  ?

• C07D 267/22 - Eight-membered rings

Abstract

The present invention provides compositions and methods for evaluating the likelihood that a tumor is sensitive to an mTOR inhibitor, e.g., rapamycin or a rapamycin analog. The invention provides FKBP proteins as biomarkers for predicting the likelihood that a tumor is sensitive to an mTOR inhibitor. The methods include assessing the expression or activity of an FKBP protein, e.g., FKBP 12, in a subject with a tumor or in a sample derived from a tumor. Additional biomarkers and biomarker combinations are also provided. The invention also provides kits containing, e.g., a validated antibody or ligand for assessing the expression or activity of an FKBP protein.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions